2012 Spinofix /Onciomed Inc.投資說明會(2012/3/13)

March 7th, 2012 | Categories: 2012 | Tags:

「ONCIOMED & SPINOFIX股份有限公司」目前正積極規劃來台尋找下一階段之技術移轉生產合作,本組僅訂於101年3月13日(星期二)下午2:00~4:30協助該公司召開投資說明會,冀能尋找有志一同的合作夥伴及資金挹注。該公司總裁Dr. Raj Nihalani 親自介紹該公司的產品、技術、公司營運計畫與未來展望,歡迎各位先進共襄盛舉並蒞臨指導!

指導單位:經濟部工業局
主辦單位:
經濟部生技醫藥產業發展推動小組
財團法人生物技術開發中心
Spinofix /Onciomed Inc.

時 間:101年3月13日(二) 14:00~16:30
地 點:小組會議室 (台北市南港區園區街3號F棟17樓)
報名方式:網路報名
聯絡人:李彩月 (電話: 02-2655-8133 ext 113)
信箱 annylee(at)biopharm.org.tw

肥胖是影響健康的關鍵因素,肥胖可能導致代謝症候群進而引發相關疾病(如:糖尿病、高血壓、心血管疾病…等),美國有1/4的人口是屬於肥胖族群,在過去十年內肥胖的盛行率已超過60%。歐美地區和新興國家肥胖症與糖尿病治療產品的需求逐年增加,如何能有效抑制肥胖成為市場新寵兒。ONCIOMED成功開發出之低侵入性外科裝置,可有效抑制肥胖,並可避免術後式可能產生之相關後遺症。產品採用生物相容性材料,已在人體使用多年,安全無虞,經過動物試驗合格,取得美國專利,製造廠符合GMP。

背痛佔美國醫療給付第三名,僅次於心臟病與癌症,診斷、治療與復健的金額每年超過50億美元,主要肇因於老化、生活型態不健康與肥胖。在退化性疾病、畸形與脊椎骨折的患者身上,脊椎植入物已被廣泛使用於固定或融合脊椎,如Posterior Pedicle Screw Fusion System(脊椎螺桿融合),市值大約25億美元,遠大於其他藥物治療或植入方式。SPINOFIX研發團隊所開發的創新脊椎植入物,結合醫療,工程師,以及脊椎專業人員,成功開發符合人體工學,滿足臨床需求,,可解決患者使用傳統治療方式所可能產生的不便及相關後遺症,獲得骨科醫師肯定,可提供安全脊椎融合手術。創新設計所需零件較少,使用便利容易適應,有助於降低整體醫療成本。產品安全、有效符合法規要求。產品專利申請中,已取得CE標誌,GMP製造廠以確定,預計今年第二季取得FDA上市許可。

該公司之英文簡介內容如下:
SPINOFIX
Orange-County Based Medical Device Company: Spinofix, Inc. was founded in 2010 by Raj Nihalani, MD in Irvine, California as a Delaware Corporation.
•Patent-Pending Technology:•Approvals In-Process: FDA510(k) and CE mark approvals in process and expected by Q2 2012.•Research and Development/ Part of a $7 Billion Market/•Aging Population Driving Growing Demand/•Minimally Invasive Approaches Receiving Mixed Feedback: Steep learning curve for MIS; extensive training time required; ongoing debate about relative outcomes. Limited Alternatives to Fixation: Many dynamic technologies are not ready for commercial use and lack long-term clinical data.

ONCIOMED
An innovative medical device company based out of Irvine, California focused on the development of proprietary, less invasive medical device technology for the treatment of obesity and diabetes.

The prevalence of obesity has increased more than 60% in the past decade. The obesity market generated more than US $303 million in 2003, this figure is expected to increase to over US $700 billion by 2015. Onciomed’s novel technology, the GVS System, enables doctors to perform a procedure that can restrict the food intake and provide the feeling of fullness. The implanted procedure is fully reversible and minimally invasive.

Principal: Raj Nihalani, CEO
Dr. Raj Nihalani, a physician by training, has 15 years of experience in the medical device industry regulatory as a regulatory, technology assessment and clinical trial consultant for medical device companies like Guidant and B Braun, and held senior positions at Medtronic. He has also worked successfully with start-up organizations including Endologix (ELGX) acquired by Radiance Med Systems, AcuFocus (Acquired by B&L), Alvivo Vascular, and as VP of Clinical Affairs at Rox Medical.

議程(Agenda):

時間Time

題目Topic

13:40~14:00

報到Registration

14:00~14:10

致詞、介紹Opening Remarks

14:10~15:10

Dr. Raj Nihalani -產品、技術、公司營運計畫介紹

Introduction of product, technology, and business plan

15:10~15:30

Q&A

15:30~16:30

會後面談Networking

|

Referrer Plugin made by Electric Guitars.